VIPGC-NOAlternative Names: 28a-Glycine-28b-(S-nitroso-L-cysteinamide)-vasoactive intestinal octacosapeptide; VIP-Gly-Cys-NO
Latest Information Update: 05 Sep 2002
At a glance
- Originator La Jolla Pharmaceutical Company; Nonindustrial sources
- Class Neuropeptides
- Mechanism of Action Nitric oxide stimulants; Vasoactive intestinal peptide receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Male sexual dysfunction
Most Recent Events
- 02 Nov 1999 New profile
- 02 Nov 1999 Preclinical development for Male sexual dysfunction in USA (Unknown route)